Three MNCs Denied India Price Increases For Eye, Diabetes Products
This article was originally published in PharmAsia News
Allergan, Novartis and Sanofi have been denied India permission to increase the prices of certain imported drugs on grounds they failed to persuade the National Pharmaceutical Pricing Authority they were justified.
You may also be interested in...
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
The US FDA’s Circulatory System Devices advisory panel will meet on 27 October to discuss the review of the premarket approval application of Neovasc’s Reducer device, which is intended to treat angina. See what Neovasc’s CEO Fred Colen said about it here.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.